Javier Corral De La Calle-rekin lankidetzan egindako argitalpenak (43)

2023

  1. Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases

    International Journal of Molecular Sciences, Vol. 24, Núm. 22

2021

  1. Anticoagulant therapy in patients with congenital FXI deficiency

    Blood Advances, Vol. 5, Núm. 20, pp. 4083-4086

2020

  1. ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant

    Molecular Genetics and Genomic Medicine, Vol. 8, Núm. 8

  2. Factor XII in PMM2-CDG patients: Role of N-glycosylation in the secretion and function of the first element of the contact pathway

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

2018

  1. Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency

    Thrombosis Research, Vol. 163, pp. 64-70

2017

  1. High incidence of FXI deficiency in a Spanish town caused by 11 different mutations and the first duplication of F11: Results from the Yecla study

    Haemophilia, Vol. 23, Núm. 6, pp. e488-e496

2016

  1. Genotype-guided therapy improves initial acenocoumarol dosing: Results from a prospective randomised study

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 117-125

  2. Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect

    Journal of Thrombosis and Haemostasis, Vol. 14, Núm. 8, pp. 1549-1560

2015

  1. A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event

    Thrombosis Research, Vol. 136, Núm. 3, pp. 634-641

2014

  1. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment

    Pharmacogenomics, Vol. 15, Núm. 7, pp. 987-996

2013

  1. Association of the thrombomodulin gene c.1418c7gt;t polymorphism with thrombomodulin levels and with venous thrombosis risk

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 6, pp. 1435-1440

  2. Creating a genotype-based dosing algorithm for acenocoumarol steady dose

    Thrombosis and Haemostasis, Vol. 109, Núm. 1, pp. 146-153

  3. Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle

    Molecular Medicine, Vol. 18, Núm. 11, pp. 1466-1472

2011

  1. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome

    Journal of Thrombosis and Haemostasis, Vol. 9, Núm. 10, pp. 1985-1992

2010

  1. Deep venous thrombosis or pulmonary embolism and factor V leiden: Enigma or paradox

    Haematologica

  2. Influence of the F12-4 C>T polymorphism on hemostatic tests

    Blood Coagulation and Fibrinolysis, Vol. 21, Núm. 7, pp. 632-639

  3. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements

    Journal of Thrombosis and Haemostasis, Vol. 8, Núm. 5, pp. 1012-1017

  4. Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders

    Annals of Hematology, Vol. 89, Núm. 11, pp. 1147-1154

  5. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

    Thrombosis and Haemostasis